Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John P Maxwell

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Bioorganic & Medicinal Chemistry Letters|March 31, 2004
Inhibitors of hepatitis C virus NS3.4A protease. Part 3: P2 proline variantsRobert B Perni, Luc J Farmer, Kevin M Cottrell, et al.
Bioorganic & Medicinal Chemistry Letters|January 12, 2015
Synthesis and evaluation of NS5A inhibitors containing diverse heteroaromatic coresJames A Henderson, Darius Bilimoria, Monica Bubenik, et al.
Cancer Discovery|April 19, 2026
TNG961 is a selective oral HBS1L molecular glue degrader for the treatment of FOCAD-deleted cancersHilary E Nicholson, Douglas A Whittington, Frank J Bruzzese, et al.
Bioorganic & Medicinal Chemistry Letters|January 12, 2015
Benzimidazole-containing HCV NS5A inhibitors: effect of 4-substituted pyrrolidines in balancing genotype 1a and 1b potencyJames A Henderson, Darius Bilimoria, Monica Bubenik, et al.
Cancer Research|August 29, 2025
TNG260 is a Small-Molecule CoREST Inhibitor that Sensitizes STK11-Mutant Tumors to Anti-PD-1 ImmunotherapyLeanne G Ahronian, Soumyadip Sahu, Minjie Zhang, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Bioorganic & Medicinal Chemistry Letters|March 31, 2004
Inhibitors of hepatitis C virus NS3.4A protease. Part 3: P2 proline variantsRobert B Perni, Luc J Farmer, Kevin M Cottrell, et al.
Bioorganic & Medicinal Chemistry Letters|January 12, 2015
Synthesis and evaluation of NS5A inhibitors containing diverse heteroaromatic coresJames A Henderson, Darius Bilimoria, Monica Bubenik, et al.
Cancer Discovery|April 19, 2026
TNG961 is a selective oral HBS1L molecular glue degrader for the treatment of FOCAD-deleted cancersHilary E Nicholson, Douglas A Whittington, Frank J Bruzzese, et al.
Bioorganic & Medicinal Chemistry Letters|January 12, 2015
Benzimidazole-containing HCV NS5A inhibitors: effect of 4-substituted pyrrolidines in balancing genotype 1a and 1b potencyJames A Henderson, Darius Bilimoria, Monica Bubenik, et al.
Cancer Research|August 29, 2025
TNG260 is a Small-Molecule CoREST Inhibitor that Sensitizes STK11-Mutant Tumors to Anti-PD-1 ImmunotherapyLeanne G Ahronian, Soumyadip Sahu, Minjie Zhang, et al.
Pageof 3